JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

In microarray gene expression experiments, several diverse conditions in each experiment (e.g., time, doses, replicates) increase the data points from tens of thousands of measurements for a single ...

Like it or not, biologists have to deal increasingly in informatics as their experiments generate ever larger and more complex data sets. Few laboratories have the resources to develop their own ...

The Geniom® RT Analyzer, a new benchtop microarray processing instrument, was presented by febit at Select Bioscience’s “Advances in Microarray Technology”. The platform complements Geniom® One, the ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of ...

Microarray image analysis has long been recognised as a pivotal methodology for quantifying gene expression across thousands of genes simultaneously. By converting intricate patterns of hybridised ...

As a graduate student, Eric Olson learned something about DNA microarrays: Biochip data management can be vexing. His graduate adviser abandoned a number of microarray experiments because it was too ...

New Haven, Conn. — Yale University researcher Michael Snyder and his colleagues have created the first microchip able to analyze virtually all yeast proteins, the chemicals that carry out the ...

In multivariate analysis, E-cad expression was the only independent prognostic factor for survival in addition to age, node status, tumor status, and pathologic surgical margins. CONCLUSION: Reduced ...

DUBLIN--(BUSINESS WIRE)--The "China Microarray Market Size, Share, Forecast, & Trend Analysis by Product, Application, End User- Forecast to 2031" report has been added to ResearchAndMarkets.com's ...

A multicenter sequential phase IV study of oxaliplatin (Oxa) and capecitabine (Cap) followed by irinotecan (Iri) and capecitabine in first line advanced colorectal cancer (ACC). Preliminary results ...